发明名称 |
Rekombinant, humanisert antistoff 2C4 (rhuMab 2C4) for anvendelse i en frem-gangsmåte for behandling av kreft i en pasient og anvendelse derav for fremstilling av et medikament |
摘要 |
Tumors are identified as responsive to treatment with anti-HER2 antibodies by detecting the presence of a HER2/HER3 and/or HER2/HER1 protein complex or for HER2 phosphorylation in a sample of tumor cells. Patients suffering from a tumor comprising HER/2/HER1 and/or HER2/HER3 heterodimers and/or HER2 phosphorylation are treated with anti-HER2 antibodies, such as rhuMAb 2C4. |
申请公布号 |
NO337855(B1) |
申请公布日期 |
2016.07.04 |
申请号 |
NO20050000775 |
申请日期 |
2005.02.14 |
申请人 |
F HOFFMANN-LA ROCHE AG |
发明人 |
SLIWKOWSKI MARK;KOLL HANS;BOSSENMAIER BIRGIT;MÜLLER HANS-JOACHIM;KELSEY STEPHEN MICHAEL |
分类号 |
A61K39/395;C07K14/485;C07K16/32;G01N33/50;G01N33/53;G01N33/574 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|